Immune related adverse events (irAEs) have been observed with all checkpoint inhibitors and are very frequent. The evidences coming from experimental models of congenital or acquired deficiency of CTLA-4 or from PD-1 knock-out mice, provided all the informations to interpret the organ or systemic manifestations (endocrine, or systemic autoimmune chronic inflammatory diseases-ACIDs) observed in trials as well as in registries of cohorts treated with anti-CTLA-4 or anti-PD-1/PD-L1 inhibitors, or combination therapies. Finally the concern raised by cancers occurring in patients with autoimmune diseases (Systemic Lupus Erythematosus, Myositis, Rheumatoid Arthritis, Psoriatic Arthritis, Vasculitis, Scleroderma, Polymyalgia Rheumatica and others) and how to deal with immunotherapy was discussed. The biological knowledges acquired with the immunotherapy trials, have paved to way to better treat autoimmune diseases in patients developing cancer during the autoimmune illness. Immunotherapy without Autoimmunity is the unmet need within our reach in the future.

中文翻译：

---

检查点抑制剂（CPI）和自身免疫性慢性炎性疾病（ACIDs）：在免疫性风湿病表现的发生中耐受性和耐受性丧失。

在所有检查点抑制剂中均观察到了与免疫相关的不良事件（irAE），并且非常频繁。来自先天性或后天性CTLA-4缺乏症的实验模型或PD-1基因敲除小鼠的证据，提供了解释在器官中观察到的器官或全身表现（内分泌或全身性自身免疫性慢性炎性疾病-ACIDs）的所有信息。试验以及在使用抗CTLA-4或抗PD-1 / PD-L1抑制剂或联合疗法治疗的队列中。最后，讨论了自身免疫性疾病（系统性红斑狼疮，肌炎，类风湿性关节炎，牛皮癣性关节炎，血管炎，硬皮病，风湿性多肌痛等）中癌症引起的关注，以及如何应对免疫疗法。免疫疗法试验获得的生物学知识为在自身免疫性疾病期间罹患癌症的患者更好地治疗自身免疫性疾病铺平了道路。没有自身免疫的免疫疗法是我们未来无法满足的需求。